{"product_id":"sr-9009-sr-9011","title":"SR-9009 + SR-9011","description":"\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003eSR-9009 (Stenabolic) + SR-9011 (REV-ERB Agonist) | Metabolic Research UK\u003c\/h2\u003e\n\u003ch2 class=\"PDq2pG_selectionAnchorContainer\"\u003e\n\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003eMetabolic Activity Research Set \u003c\/h2\u003e\n\u003cp\u003eThe BioPlex Metabolic Activity Research Set combines SR-9009 (Stenabolic) 50×15mg and SR-9011 (REV-ERB Agonist) 50×15mg, bringing together two closely related synthetic research compounds developed for investigation of REV-ERB-associated signalling, circadian biology and metabolic regulation. The set contains one pot of each compound and provides a structured format for comparative laboratory research into two molecules that share a closely connected research history while retaining distinct chemical identities.\u003c\/p\u003e\n\u003cp\u003eUnlike compounds such as RAD-140, Ostarine or LGD-4033, SR-9009 and SR-9011 are not selective androgen receptor modulators. Their research history instead centres on REV-ERBα and REV-ERBβ, nuclear receptors involved in biological pathways connecting circadian rhythms, transcriptional regulation and cellular metabolism. This distinction is important when interpreting the scientific purpose of the set.\u003c\/p\u003e\n\u003cp\u003eSR-9009, widely known as Stenabolic, is the better-known of the two compounds and has been investigated in experimental models examining circadian behaviour, metabolic gene expression, mitochondrial-associated processes and energy metabolism. SR-9011 was developed within the same broader research programme and provides a related synthetic ligand for studying REV-ERB-associated pathways.\u003c\/p\u003e\n\u003cp\u003eTheir close relationship makes this pairing useful for comparative laboratory investigation. Rather than combining unrelated mechanisms, researchers can examine two structurally distinct compounds developed around the same nuclear-receptor research system.\u003c\/p\u003e\n\u003cp\u003eThe Metabolic Activity Research Set name reflects this principal scientific theme. It does not imply that either compound will produce predetermined metabolic outcomes, and later research has raised important questions about whether all experimental observations attributed to SR-9009 are mediated exclusively through REV-ERB.\u003c\/p\u003e\n\u003cp\u003eTogether, SR-9009 and SR-9011 provide a focused BioPlex pairing for laboratory investigation of metabolic signalling, circadian pathways and REV-ERB-associated research while maintaining appropriate distinction between established findings and mechanistic hypotheses.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eHow SR-9009 and SR-9011 Work Together\u003c\/h2\u003e\n\u003cp\u003eSR-9009 and SR-9011 were developed as synthetic compounds for investigating REV-ERB-associated signalling. REV-ERBα and REV-ERBβ are members of the nuclear-receptor family and participate in transcriptional networks connecting the molecular circadian clock with metabolic regulation. This shared research pathway provides the scientific rationale for presenting SR-9009 and SR-9011 together.\u003c\/p\u003e\n\u003cp\u003eREV-ERB receptors participate in regulation of gene expression rather than functioning through the androgen receptor targeted by genuine SARMs. This makes the SR pairing mechanistically different from the androgen-receptor combinations elsewhere in the BioPlex research range.\u003c\/p\u003e\n\u003cp\u003eExperimental investigation of synthetic REV-ERB ligands has examined pathways associated with circadian regulation, metabolic gene expression, lipid and glucose metabolism, mitochondrial function and energy-related cellular processes. SR-9009 and SR-9011 have consequently become useful experimental tools for investigating how pharmacological modulation of these pathways may alter measurable biological markers.\u003c\/p\u003e\n\u003cp\u003eHowever, their relationship should not be oversimplified. Two compounds developed against the same receptor system do not necessarily demonstrate identical potency, selectivity, pharmacokinetics or downstream experimental effects. Chemical structure, concentration, cellular environment and experimental model can influence observations.\u003c\/p\u003e\n\u003cp\u003eThere is another important scientific consideration. Later research involving SR-9009 reported biological effects that persisted in experimental systems lacking functional REV-ERBα\/β, raising evidence that at least some effects of SR-9009 can occur independently of REV-ERB. Consequently, describing every observed SR-9009 response as a direct result of REV-ERB activation would overstate the evidence.\u003c\/p\u003e\n\u003cp\u003eThe value of this combination therefore lies in controlled comparison rather than assuming synergy. SR-9009 and SR-9011 allow researchers to investigate two related synthetic ligands within circadian and metabolic research while examining receptor-dependent and potentially receptor-independent mechanisms under carefully defined experimental conditions.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eSR-9009 (Stenabolic) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eSR-9009, commonly known as Stenabolic, is a synthetic research compound developed during investigation of the nuclear receptors REV-ERBα and REV-ERBβ. Although frequently grouped commercially with SARMs, SR-9009 is not a selective androgen receptor modulator and does not belong to the same primary pharmacological category as compounds such as Ostarine, RAD-140 or LGD-4033.\u003c\/p\u003e\n\u003cp\u003eIts research significance originates from the role of REV-ERB receptors in the molecular circadian clock and metabolic regulation. Nuclear receptors can influence transcriptional activity in response to molecular interactions, and REV-ERB proteins participate in networks regulating circadian gene expression and metabolic processes.\u003c\/p\u003e\n\u003cp\u003eEarly experimental research using SR-9009 investigated whether synthetic pharmacological modulation of REV-ERB-associated pathways could alter measurable circadian and metabolic parameters. This produced research interest in areas including metabolic gene expression, energy utilisation, mitochondrial-associated activity and related cellular processes.\u003c\/p\u003e\n\u003cp\u003eHowever, subsequent research complicated the original mechanistic interpretation. Experimental studies have reported SR-9009-associated effects in models where REV-ERB activity was absent or disrupted. These findings indicate that at least some observations associated with SR-9009 may involve mechanisms beyond direct REV-ERB activation.\u003c\/p\u003e\n\u003cp\u003eThis distinction is scientifically important. SR-9009 remains valuable as an experimental research compound, but results should not automatically be interpreted as proof of a purely REV-ERB-dependent mechanism. Researchers should distinguish between observed biological responses and conclusions about the precise molecular pathway producing those responses.\u003c\/p\u003e\n\u003cp\u003eWithin the Metabolic Activity Research Set, SR-9009 provides the better-known component of the pairing. Its extensive use in metabolic and circadian research provides a useful comparison point for SR-9011 while allowing receptor-specific hypotheses, alternative mechanisms and compound-dependent experimental differences to be investigated independently.\u003c\/p\u003e\n\u003ch2\u003e\u003cbr\u003e\u003c\/h2\u003e\n\u003ch2\u003eSR-9011 (REV-ERB Agonist) 50×15mg\u003c\/h2\u003e\n\u003cp\u003eSR-9011 is a synthetic research compound developed within the same broader programme of investigation into pharmacological modulation of REV-ERB nuclear receptors as SR-9009. It is commonly described within scientific and research-compound literature as a synthetic REV-ERB ligand or agonist and has been investigated in experimental systems involving circadian regulation, transcriptional signalling and metabolic biology.\u003c\/p\u003e\n\u003cp\u003eLike SR-9009, SR-9011 is not a selective androgen receptor modulator. Its principal research classification instead relates to REV-ERBα and REV-ERBβ, nuclear receptors that participate in transcriptional networks connecting circadian timing with metabolic processes.\u003c\/p\u003e\n\u003cp\u003eThis pathway makes SR-9011 useful for laboratory investigation of how synthetic ligands may influence REV-ERB-associated transcription and downstream biological markers. Experimental areas can include circadian gene expression, cellular metabolic signalling and other predetermined endpoints relevant to nuclear-receptor biology.\u003c\/p\u003e\n\u003cp\u003eSR-9011 should nevertheless be evaluated independently rather than assuming that every observation made with SR-9009 applies equally to it. Structurally related compounds can differ in receptor interaction, concentration-response relationships, stability, cellular exposure and off-target behaviour. These differences are particularly important when the objective of research is to understand mechanism rather than simply document an observed response.\u003c\/p\u003e\n\u003cp\u003eWithin the BioPlex Metabolic Activity Research Set, SR-9011 therefore provides the second component of a closely related comparative pairing. SR-9009 offers the larger and more widely discussed experimental history, while SR-9011 enables investigation of another synthetic compound associated with the same broader nuclear-receptor pathway.\u003c\/p\u003e\n\u003cp\u003eUsed as separate experimental compounds within the same research framework, SR-9009 and SR-9011 can support comparative investigation of REV-ERB-associated signalling, circadian biology and metabolic pathways without incorrectly classifying either compound as a SARM or assuming that their experimental behaviour is identical.\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Compounds\u003c\/h3\u003e\n\u003cp\u003eContinue exploring related metabolic, nuclear-receptor and research compounds from the BioPlex range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SR-9009 Stenabolic | Metabolic Research Capsules | BioPlex UK\"\u003eView SR-9009 Stenabolic 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SR-9011 REV-ERB Agonist | Metabolic Research Capsules | BioPlex UK\"\u003eView SR-9011 REV-ERB Agonist 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"MK-677 Ibutamoren | Research Capsules | BioPlex UK\"\u003eView MK-677 Ibutamoren 50×15mg Research Capsules ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore BioPlex Research Information\u003c\/h3\u003e\n\u003cp\u003eAccess BioPlex research guidance, compound classification and the complete research product range.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"SARMs and Related Research Compounds Guide 2026 | BioPlex Peptides\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/sarms\" title=\"SARMs and Research Compounds UK | BioPlex Peptides\"\u003eExplore the BioPlex SARMs \u0026amp; Research Compound Range ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/collections\/all-products\" title=\"All Research Products UK | Peptides, SARMs \u0026amp; Solutions | BioPlex Peptides\"\u003eView All BioPlex Research Products ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eExplore Related Research Articles\u003c\/h3\u003e\n\u003cp\u003eContinue your research with BioPlex articles covering compound classification, metabolic research compounds and the distinction between SARMs and compounds operating through different molecular pathways.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-mk-677-ibutamoren-is-not-a-sarm\" title=\"MK-677 Ibutamoren Is Not a SARM | Research Classification | BioPlex Peptides\"\u003eRead Why MK-677 Ibutamoren Is Not a SARM ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\/science-research-studies-complete-guide-to-sarms-uk-research-compounds-explained-for-2026\" title=\"SR-9009 SR-9011 and Research Compound Classification | BioPlex Peptides\"\u003eRead the Complete SARMs UK Research Compound Guide ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/bioplexpeptides.co.uk\/blogs\/sarms-research-articles-bioplex-peptides-uk\" title=\"SARMs \u0026amp; Research Compound Articles | BioPlex Peptides UK\"\u003eExplore All BioPlex SARMs Research Articles ⟶\u003c\/a\u003e\u003c\/p\u003e\n\u003ch2\u003e\n\u003cbr\u003eDisclaimer\u003c\/h2\u003e\n\u003cp\u003e\u003ca title=\"Legal Notice | BioPlex Peptides UK\" rel=\"noopener\" class=\"decorated-link\" href=\"https:\/\/bioplexpeptides.co.uk\/policies\/legal-notice?utm_source=chatgpt.com\"\u003eFor research purposes only. Not for human consumption.\u003c\/a\u003e\u003c\/p\u003e","brand":"BioPlex Peptides","offers":[{"title":"Default Title","offer_id":58753225851264,"sku":null,"price":93.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0991\/6783\/0400\/files\/SR-9009_SR-9011.png?v=1787432562","url":"https:\/\/bioplexpeptides.co.uk\/tr\/products\/sr-9009-sr-9011","provider":"BioPlexPeptides.co.uk","version":"1.0","type":"link"}